Jump to content
Sign in to follow this  
boron

Regeneron, expectations for 2018

Recommended Posts

Is REGN in a buy territory? May want to wait for a dip below $290

Share this post


Link to post
Share on other sites

Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 results ($M): Revenues: 1,511 (+14.6%); Sanofi collaboration revenue: 189 (-10.0%); Bayer collaboration revenue: 248 (+27.8%).

Key product sales: EYLEA (U.S.): 984 (+15.2%), EYLEA (ex-U.S.): 624 (+28.9%); Praluent: 60 (+66.7%); Dupixent: 131; Kevzara: 12; ZALTRAP: 26 (+52.9%); ARCALYST: 4 (flat).

Sanofi sales: 229 (+332.1%).

Net income: 478 (+92.0%); non-GAAP net income: 537 (+59.3%); EPS: 4.16 (+92.6%); non-GAAP EPS: 4.67 (+59.9%).

2018 Guidance: Sanofi collaboration revenue: $450M - 485M from $450M - 500M.

Share this post


Link to post
Share on other sites

The company growth for the next two years is about 9% in revenue and roughly 20% in EPS. This is double the MRK's. Based on the growth rate, REGN should be trading in a forward-looking condition at around 20 PE or around $400 per share considering 2019 EPS expectations. The additions to revenue could make the price higher. 

Analysts actually expect such a price. 

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  



  • Member Statistics

    • Total Members
      3
    • Most Online
      492

    Newest Member
    Zodiakleo
    Joined
×